June Cancer Awareness
In December 2016, the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI) announced a major collaboration focused on an emerging area of cancer research: neoantigens. These small proteins on the surface of cancer cells arise from mutations often unique to a tumor, making personalized immunotherapies like cancer vaccines a possibility.
Roswell Park is proud to have been part of this exciting collaboration from its inception. Kunle Odunsi, MD, PhD, Executive Director, Center for Immunotherapy, recently shared a blog post outlining the power of neoantigens and why researchers see such promise within.
From the Cancer Talk Blog
In the News
Immunotherapy Expert Dr. Pawel Kalinski Joins Roswell Park Cancer Institute
Friday, April 27, 2017
New Adoptive Cell Therapy Immunotherapy Approach Ready for Clinical Trials
Tuesday, April 4, 2017
New Ovarian Cancer Immunotherapy Study Poses Question: Can Microbiome Influence Treatment Response?
Monday, November 28, 2016